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Arterial hypertension is one of the main contributors to cardiovascular diseases, including stroke, heart
failure, and coronary heart disease. Salt plays a major role in the regulation of blood pressure and is
one of the most critical factors for hypertension and stroke. At the individual level, effective salt reduction
is difficult to achieve and available methods for managing sodium balance are lacking for many patients.
As part of the ingested food, salt is absorbed in the gastrointestinal tract by the sodium proton exchanger
subtype 3 (NHE3 also known as Slc9a3), influencing extracellular fluid volume and blood pressure.
In this review, we discuss the beneficial effects of pharmacological inhibition of NHE3-mediated
sodium absorption in the gut and focus on the effect on blood pressure and end-organ damage.
 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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Arterial hypertension is the leading cause of cardiovascular dis-
eases and predominantly linked to stroke, heart failure and coro-
nary heart disease [1]. There is a considerable body of evidence
associating higher salt intake with higher blood pressure and
increased cardiovascular risk, namely hypertension and stroke
[2–5]. Moreover, excess sodium intake impairs beneficial effects
of different antihypertensive drugs, including blockers of the
renin–angiotensin-aldosterone system (RAAS), one of the key-
point pharmacological interventions in cardiovascular and renal
medicine [6].
In many countries, the usual sodium intake is between 3.5 and
5.5 g per day, which equals a salt consumption of 9–12 g/day [7]. A
3 g/day reduction in salt intake decreases on average systolic and
diastolic pressure by 5 and 2 mmHg, respectively. The effect is
more pronounced in hypertensive, black or elderly people and in
individuals with diabetes, metabolic syndrome or chronic kidney
disease (CKD). Here, salt restriction does not only lower blood
pressure but may also reduce the number and doses of antihyper-
tensive drugs [8]. Thus guidelines recommend a maximum daily
intake of 5 g of salt (about 2 g (46 mmol) of sodium per day) for
the general population [7].
Given the dilemma of a low-salt diet, which is notoriously diffi-
cult to achieve but yet bears fundamental benefits on cardiovascu-
lar health, this review discusses intestinal pharmacological sodium
uptake inhibition as a novel cardiovascular treatment strategy.1.1. Sodium homeostasis
Sodium homeostasis is closely linked to fluid balancing and
blood pressure regulation. Aside from the kidney, muscle, skin
and brain, the gut, as the organ to absorb ingested sodium, has
been suggested to be involved in sodium homeostasis [9–11].
In the kidney, the renal proximal tubule is responsible for 65–
70% of filtered sodium and water reabsorption under normal con-
ditions [12]. Several studies have shown that human essential
hypertension is associated with increased sodium transport in
the renal proximal tubule [13]. The inappropriate sodium retention
in hypertension results from an enhanced renal sodium transport
per se, as well as a failure to respond appropriately to signals that
decrease renal sodium transport in the face of increased sodium
intake.Fig. 1. NHE3 gene expression profile (A) and mechanism of sodium absorption in the sm
(PAT1), down regulated in adenoma (DRA) [18,20].
Downloaded for Anonymous User (n/a) at BS - University of Copen
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in maintaining salt and fluid balance [14]. Humans reabsorb about
7–9 L of gastrointestinal fluid a day. Most of the electrolytes and
fluids are absorbed by the small (>95%) and large (>4%) intestines.
The intestinal absorption of fluid by gastrointestinal epithelial
cells, mainly located from the small intestine to the distal colon,
occurs via active transport of sodium. Experiments on Dahl salt-
sensitive and salt-resistant rats, which represent a model of salt-
sensitive hypertension, have shown no difference in intestinal
sodium absorption between hypertensive and healthy controls
[15]. Thus, an augmented ability of the intestines to absorb sodium
does not critically participate in the pathogenesis of most cases of
hypertension.1.2. Sodium-proton-exchangers in the gut and the gastrointestinal-
renal axis
Intestinal salt (NaCl) and water absorption in the gut are largely
driven by the sodium-dependent cotransporters and sodium reup-
take, including the sodium-proton-exchangers NHE2, NHE3, and
NHE8, of which NHE3 (SLC9A3) is of main importance [16].
NHE3 is highly expressed at the apical membrane of the small
intestine and colon [17,18] and NHE3 knock-out mice are mainly
characterized by defects in intestinal sodium absorption [19],
demonstrating that NHE3 is the major contributor to intestinal
sodium uptake (Fig. 1). NHE3 exchanges sodium (Na+) for protons
(H+), while the protons are provided by water and carbon dioxide,
which is transformed to H2CO3 by the enzyme carbonic anhydrase.
The initiator, which allows sodium to cross the cell border due to
creating an electrochemical gradient is the basolateral Na-K-
ATPase. Moreover, putative-anion-transporter-1 (PAT1) and
down-regulated-in-adenoma (DRA) are both transporters involved
in the absorption of chloride (Cl) [20].
Not only are the gut and the kidneys both involved in maintain-
ing sodium and fluid balance and thereby blood pressure, there is
even evidence suggesting a hormonal communication between the
two organs [21]. The gastrointestinal tract screens the food via
taste receptors and sensors for electrolytes (eg. sodium, potassium,
phosphate) [22]. Gastrointestinal tract–derived hormones and
peptides have been shown to regulate autocrine function of renal
hormones, including gastrin and glucagon-like-Peptide-1, affecting
renal function and mediating sodium excretion [23]. This suggests
the existence of a gastrointestinal–renal axis regulating blood pres-
sure [21].all intestine (B). Sodium hydrogen exchanger 3 (NHE3), putative anion transporter 1
hagen from ClinicalKey.com by Elsevier on September 10, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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The gut is the habitat of a large variety of bacteria, fungi, viruses
and protozoa. Profound research, demonstrated that the gut micro-
biome contributes fundamentally to energy homeostasis, metabo-
lism, immunology, cardiovascular health and even
neurobehavioral development [24,25]. Therefore, malnutrition,
like excess in salt intake, may have wide ranging consequences.
In mice, high salt intake affects the gut microbiome, particularly
by depleting Lactobacillus murinus [26]. Consequently, treatment
of mice with Lactobacillus murinus prevented salt-induced aggra-
vation of actively induced experimental autoimmune
encephalomyelitis and salt-sensitive hypertension by modulating
T-helper 17 (TH17) cells. In line with these findings, a moderate
high-salt challenge in a pilot study in humans reduced intestinal
survival of Lactobacillus, increased TH17 cells and increased blood
pressure [26]. Moreover, high dietary sodium consumption also
depletes bacteria from the order Clostridiales [26], which together
with Lactobacillus species, are crucial for the secondary bile acid
metabolism [10]. Deoxycholic and lithocholic acids are ligands
for G-protein-coupled bile acid receptor 1, expressed along the gas-
trointestinal tract, which upon activation increase expression of
cystathionine c-lyase, an essential enzyme for generation of the
vasodilator hydrogen sulfide [10]. This generally stresses the
importance of the gut microbiome for cardiovascular physiology.
Moreover though, microbiome composition is easily affected by
changes of intestinal pH, which is modulated amongst others by
intestinal NHE3 [27].
1.4. Intestinal inhibition of sodium uptake: a new antihypertensive
concept?
Effective salt reduction is a recommended lifestyle change in
order to treat hypertension, but at an individual level hard to
achieve. Available methods for managing sodium and fluid balance,
like a substantial and radical change in diet is not a possibility for
many patients. Large renal trials demonstrated, that salt-ingestion
of patients was clearly far above the recommended 5–6 g/day [6]. A
novel treatment target in that area evolved recently: non-
absorbable intestinal NHE3-inhibitors. Those inhibitors are meant
to reduce intestinal sodium uptake and help with the otherwise
hardly achievable lifestyle change of a low salt-diet. NHE3-
inhibitors have special implications for patients with hypertension
and heart failure. Especially, in heart failure patients, treatment of
fluid overload by diuretics becomes rapidly inefficient as patients
develop resistance to diuretics and/or develop concomitant renal
failure and hypokalemia [28].2. Pharmacological inhibition of intestinal sodium absorption
Generally, drugs are designed to be rapidly absorbed to achieve
therapeutic plasma levels, and then be eliminated by multiple
pathways. In contrast, oral administration of non-absorbable drugs
is designed to minimize systemic exposure and to exert their ther-
apeutic effects locally in the gastrointestinal tract. Due to these dif-
ferences, the development of non-absorbable drugs is directed by
its own set of pharmaceutical design principles. Non-absorbable
and therefore non-systemic drugs display less off-target systemic
effects and thereby less drug-drug interaction, toxicity, or side-
effects (reviewed in [29]).
2.1. Non-absorbable NHE3-inhibitors
Oral administration of highly selective non-absorbable NHE3-
inhibitors reduces the intestinal water and sodium absorption inDownloaded for Anonymous User (n/a) at BS - University of Copenhag
For personal use only. No other uses without permission. Cthe gut [18,30]. These inhibitors specifically target the
membrane-bound protein-fraction of the NHE3, expressed on the
cell surface of the gut epithelia. Their non-systemic profile is char-
acterized by drug metabolism pharmacokinetic methods, tracking
parent drug and metabolites in blood, urine, and feces. Addition-
ally, absorption experiments in vessel-perfused in situ prepara-
tions of the small intestine are helpful screening-tools [18].
2.1.1. SAR218034xxx
SAR218034 (SAR, (1-(b-D-glucopyranosyl)-3-{3-[(4S)-6,8-dichl
oro-2-methyl-1,2,3,4-tetrahydroisochinolin-4-yl]phenyl}urea) is a
novel, non-absorbable NHE3-inhibitor [18]. SAR demonstrated
high potency and selectivity in rat studies and has approximately
equivalent inhibitor action on rat and human NHE3. SAR did not
interact with the physiological functions of other human NHE-
isoforms, like NHE5 or NHE1. Amino acid sequence comparison
revealed high homologies between orthologous NHE proteins in
rats and humans ranging from 90% to 98% identity [18].
Bioavailability of SAR is very low as demonstrated in a perme-
ability assay (Caco-2 in TC7 cells) and in oral bioavailability stud-
ies. An oral dose of 1 mg/kg as used in preclinical study
corresponds to a maximal plasma concentration of 1 nmol/L. This
is 13-fold below the half maximal inhibitory concentration (IC50)
for rat NHE3. Therefore, SAR is a functional non-absorbable com-
pound. Additionally, in perfused in situ preparations of the small
intestine, intraluminal SAR application increased sodium concen-
tration and volume of the perfusate. This underlines the local effect
of SAR at the luminal intestinal membrane.
In both lean and obese spontaneously hypertensive rats (SHR
and SHR-ob), selective pharmacological inhibition of the NHE3
exchanger in the gut by SAR reduced intestinal sodium absorption
and increased renal sodium reabsorption [18] (Fig. 2).
2.1.2. Tenapanor
Effects comparable to SAR were also found by another selective
NHE3-inhibitor, tenapanor (RDX5791,AZD1722, N,N’-(10,17-dioxo-
3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis
([(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetra hydroisoquinolin-4-yl]b
enzenesulfonamide)) [31]. Tenapanor is up to now the only NHE3
inhibitor that has been evaluated in humans. After oral administra-
tion of tenapanor in rats and humans, maximal plasma concentra-
tions were less than 1 ng/ml due to limited permeability across cell
monolayers. Non-absorbance of tenapanor was also confirmed by
mass balance and quantitative whole-body autoradiography stud-
ies with 14C-tenapanor in rats [30]. The pharmacological effects of
tenapanor evaluated in rats and healthy human volunteers were
found to be comparable and include reduced urinary sodium and
increased fecal sodium, activities consistent with reduced intesti-
nal sodium absorption and increased sodium reabsorption in the
kidney [30] (Fig. 2). These data indicate that NHE3 blockade shifts
sodium from urinary to fecal excretion. Moreover, in humans the
response to tenapanor has been shown to be both dose-
dependent and reversible [32,33].
In addition to increased stool sodium excretion, tenapanor has
also been found to increase the excretion of stool phosphate and
as a result reduced serum phosphate concentrations which has
beneficial implications for patients with CKD-related hyperphos-
phatemia [34–36]. In a randomized phase 3 trial in patients with
CKD, tenapanor treatment for 8 weeks could reduce elevated
serum phosphate levels while receiving maintenance hemodialysis
[36]. Tenapanor however could in another CKD cohort not change
interdialytic weigh gain despite of increased sodium stool content
[37].
As tenapanor acts locally in the gastrointestinal tract it could
potentially cause drug-drug interactions with drugs metabolized
by the cytochrome P450 enzymes (CYPs) found in cells of the guten from ClinicalKey.com by Elsevier on September 10, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
Fig. 2. Effect of intestinal NHE3-inhibition on intestinal salt absorption and subsequent fecal and urinary salt excretion. Impact on blood pressure and feces water content.
4 B. Linz et al. / IJC Heart & Vasculature 29 (2020) 100591wall. Out of several CYPs tested in vitro, tenapanor was found to
have the most potent inhibitory effect on CYP3A4. However, clini-
cal studies have found that the effect on CYP3A4 is not clinically
relevant as the pharmacokinetic characteristics of midazolam, a
CYP3A4 metabolized drug, are comparable whether co-
administrated with tenapanor or not. Therefore, tenapanor can
be co-administrated with drugs metabolized by CYP3A4 without
any expected clinically relevant drug-drug interactions [38].
Due to the low systematic availability tenapanor is in general
reported to be well tolerated in humans with only mild to moder-
ate adverse GI adverse effects such as abdominal pain and diarrhea
[32,33]. Tenapanor was evaluated and approved for treatment of
irritable bowel syndrome with constipation. Moreover, tenapanor
is being investigated for treatment of hyperphosphatemia in
patients with end-stage renal disease on hemodialysis and peri-
toneal dialysis (ClinicalTrials.gov Identifier NCT03427125).3. Antihypertensive effects of pharmacological intestinal NHE3-
inhibition
Reduced intestinal NHE3-mediated sodium absorption in SAR-
[18] or tenapanor-treated animals [22] was associated with
decreased blood pressure in SHR and obese SHR rats, which are
models for spontaneous hypertension, as well as in 5/6 nephrec-
tomized rats, a rat model for renal loss [18,30]. Additionally, SAR
or tenapanor administered in combination with an ACE-inhibitor,
resulted in an additive reduction in blood pressure (Fig. 3).
Underlying mechanisms of the NHE3-inhibition associated anti-
hypertensive effect include a reduction in extracellular volume due
to the laxative effect, potential changes in intestinal microbiome
composition and a decreased sympathetic activation [18,39] (7.;Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permissioFig. 2). Interestingly, not only does intestinal salt absorption influ-
ence sympathetic activation, also Angiotensin II itself, as a conven-
tional result of a sympathetic activation, showed regulative effects
on intestinal epithelial NHE3 expression in cells, indicating a close
relationship between intestinal salt absorption and sympathetic
drive [40].
These results underline the importance of NHE3 regulation in
hypertension, but further randomized clinical trials of NHE3-
inhibitors in hypertensive patients are warranted.
Antihypertensive effects of intestinal NHE3-inhibiton could be
of special interest in CKD-patients, in which conventional medical
treatment strategies which often have renal targets lack efficiency.
Even though intestinal NHE3-inhibition increased sodium stool
content and decreased phosphate uptake in CKD-patients under
hemodialysis, blood pressure was not reported to be affected by
the treatment [36,37]. Nevertheless, blood pressure remains to
be a difficult parameter to assess under hemodialysis and future
clinical studies are warranted to investigate antihypertensive
effects also in such special cohorts.4. Laxative effects of pharmacological intestinal NHE3-
inhibition
Increased sodium concentration in the feces in NHE3-inhibitor
treated animals binds water in the gut. A stool water content of
60–70% in SAR-treated animals resulted in a softer but still solid
stool consistency and did not cause diarrhea [18]. Consistently,
tenapanor administration to normal rats loosened stool form
[30]. Additionally, in humans tenapanor administrations softens
stool consistency, increases stool frequency and weight and the
frequency of bowl movements [32,33]. In addition to these effects,hagen from ClinicalKey.com by Elsevier on September 10, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Fig. 3. Effect of NHE3-inhibitor SAR on systolic blood pressure (top) and feces water content (bottom) in SHR (left) and SHR-ob (right). In SHR (left) SAR was combined with
the ACE-inhibitor ramipril (RAM) [18].
B. Linz et al. / IJC Heart & Vasculature 29 (2020) 100591 5patients with irritable bowel syndrome with constipation also
reported relief of abdominal symptoms such as bloating, cramping
and discomfort [41]. However, in humans, the most common side-
effect of non-absorbable NHE3-inhibitors remains to be diarrhea
[42].5. Prevention of hypertensive cardiac and renal end-organ
damage
To further validate its therapeutic use in the setting of hyper-
tension in CKD, tenapanor was tested in 5/6 nephrectomized rats
fed a high sodium diet. NHE3-inhibition reduced blood pressure,
normalized albuminuria, and delayed heart and kidney damage
[30]. Comparable effects were also shown for the NHE3-inhibitor
SAR. Stable blood pressure reduction in NHE3-inhibitor treated
animals was associated with an attenuation of cardiac and renal
end-organ damage [43]. Furthermore, SAR also prevented atrial
structural remodeling and reduced atrial arrhythmia susceptibility
in a rat model for hypertension and metabolic syndrome [44,45].6. NHE3-inhibitors and heart failure
Up to now, salidiuretics are effectively used to improve conges-
tion in congestive heart failure, but their use is often limited by
constipation and renal failure [28]. In CKD, the ability of the kid-
neys to excrete potassium decreases proportionally to the loss of
glomerular filtration. Besides this, diuretic treatment and associ-
ated dehydration provokes constipation [46]. Increase in intestinal
water excretion is an alternative promising strategy to manageDownloaded for Anonymous User (n/a) at BS - University of Copenhag
For personal use only. No other uses without permission. Cwater load in heart failure. The modulation of intestinal sodium
uptake by non-absorbable NHE3-inhibitors instead of modulation
of sodium excretion in the kidney by diuretics did not result in
the development of hypokalemia, diabetic condition or impaired
lipid status [18]. Noteworthy, diuretics may affect intestinal
NHE3-exchanger and result in its further upregulation [47]. This
phenomenon may be particularly relevant in congestive heart fail-
ure patients receiving high-diuretic doses. NHE3-inhibitors may
however prevent the functional effect of this increased NHE3
expression.
Although a direct comparison between the net effects on the
sodium balance of the currently used diuretics and intestinal
NHE3-inhibiting compounds are not available, diuretics might also
induce sodium loss via the stool by the blockage of sodium trans-
porters and exchangers, including NHE3, which are present in both
the kidney and the intestines [48,49]. However, the relative contri-
bution of fecal sodium excretion to overall sodium excretion dur-
ing oral or intravenous diuretic treatment remains uncertain.
Interestingly, with very potent and orally highly bioavailable
NHE3 inhibitors, no significant influence on renal function, for
example, natriuresis could be observed previously (unpublished
own data). This is the reason that no renal-specific NHE3 inhibitor
was developed for clinical use.7. Potential effect of NHE3-inhibition on microbiome
composition
Changes in gut microbiome composition can either have
beneficial or detrimental consequences for human physiology.en from ClinicalKey.com by Elsevier on September 10, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
6 B. Linz et al. / IJC Heart & Vasculature 29 (2020) 100591Therefore, modulation of the gastrointestinal intraluminal milieu
by selective pharmacological inhibition of intestinal absorption of
dietary ions might offer an interesting approach to control the
composition of the gut microbiome [50,51].
Recent studies have demonstrated that NHE3-deficiency, result-
ing in alkaline gut luminal microenvironment, may alter the bacte-
rial flora of the brush border in a way that is deleterious to both
abundance of Firmicutes (particularly families Lachnospiraceae
and Ruminococcaceae) as well as butyrate production, shifting
instead to a peak production of propionate and an expansion
of Bacteroidetes [27,52]. Propionate is the strongest among short
chain fatty acids (SCFA) ligand for both G protein coupled receptors
41 and 43 [53], reported to be associated with vasodilation and
blood pressure reduction [54,55]. Moreover, propionate stimulated
the secretion of both peptide YY and glucagon-like peptide 1,
which reduce NHE3 expression enhancing negative feedback loop
[56]. In the intestine, continuous stimulation of intestinal T cells
by excessive propionate leads to the spontaneous interleukin-10
production [57], which counteracts both the pressoric activity of
angiotensin II as well as vascular dysfunction associated with
hypertension [58]. Recently, propionate administered in drinking
water to mice infused with angiotensin II reduced systolic and
diastolic blood pressure, systemic inflammation, cardiac damage,
and improved vascular function [59]. SCFA, especially butyrate,
are positive regulators of NHE3 expression and activity [27]. There-
fore, reduction in butyrate levels promote decreased activity of
NHE3, which sustains alkaline mucosal milieu to maintain a com-
petitive advantage to alkaliphilic bacteria.
Lachnospiraceae and Ruminococcaceae have been identified as
the most metabolically active bacteria of the human microbiota
and play a dominant role in the trimethylamine-N-oxide (TMAO)
production [60]. Several studies suggest an existence of a positive
feedback mechanism between TMAO and NHE3 expression [55,61]
and found serum TMAO to be associated with chronic upregulation
of blood pressure via prolonging the hypertensive effect of angio-
tensin II [62]. Hence, reduction in aforementioned bacteria species
caused by NHE3-deficiency could have positive impact on blood
pressure.
One exceptional Firmicutes is Clostridium difficile, which is
adapted to replicate optimally at a slightly higher pH than other
Clostridia species. Together with other enteropathogenic bacteria
C. difficile inhibits intestinal NHE3 expression and function lower-
ing blood pressure [63,64]. This effect is enhanced by reduction
in commensal Lactobacillus acidophilus, caused by alkaline
microenvironment, that upregulates intestinal NHE3 function
under conditions of reduced pH [65].
While these results indicate positive bacterial composition out-
comes with NHE3 inhibition, other research reports that NHE3
deficiency induces irritable bowel disease-like symptoms, gut dys-
biosis, and an inflammatory immune system response [66]. Hence,
it still remains unclear whether NHE3 inhibition is a viable thera-
peutic intervention for those with hypertension.
Further studies are needed to investigate the feasibility and effi-
cacy of altering the gut microbiome composition by oral treatment
with non-absorbable drugs specifically targeting ion transporters
such as NHE3 in the gut.8. Conclusions
Pharmacological inhibition of intestinal NHE3-mediated
sodium absorption is a novel alternative treatment strategy to
reduce sodium and water load by selective NHE3-inhibition in
the gut. Selective inhibition of NHE3-mediated sodium absorption
in the gut has the potential to reduce high blood pressure and
cardiac end-organ damage and can be safely combined with ACEDownloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permissioinhibitor treatment. Intestinal NHE3-inhibition may provide an
attractive option to clinicians managing sodium-fluid balance
and hypertension, particularly in patients with preexisting kidney
failure. The real potential of the NHE3-inhibitor is to help accom-
plish a truly low-salt intake from the gut, since it is notoriously dif-
ficult to sufficiently reduce salt in the human diet. Whether
gastrointestinal NHE3-inhibition also results in a modulation of
gut microbiome composition requires further investigation.
References
[1] M. Ezzati, A.D. Lopez, A. Rodgers, S. Vander Hoorn, C.J. Murray, G. Comparative
Risk Assessment Collaborating, Selected major risk factors and global and
regional burden of disease, Lancet 360 (9343) (2002) 1347–1360.
[2] F.M. Sacks, L.P. Svetkey, W.M. Vollmer, L.J. Appel, G.A. Bray, D. Harsha, E.
Obarzanek, P.R. Conlin, E.R. Miller 3rd, D.G. Simons-Morton, N. Karanja, P.H.
Lin, D.A.-S.C.R. Group, Effects on blood pressure of reduced dietary sodium and
the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium
Collaborative Research Group, N. Engl. J. Med. 344 (1) (2001) 3–10.
[3] S. Reuter, E. Bussemaker, M. Hausberg, H. Pavenstadt, U. Hillebrand, Effect of
excessive salt intake: role of plasma sodium, Curr. Hypertens. Rep. 11 (2)
(2009) 91–97.
[4] P. Meneton, X. Jeunemaitre, H.E. de Wardener, G.A. MacGregor, Links between
dietary salt intake, renal salt handling, blood pressure, and cardiovascular
diseases, Physiol. Rev. 85 (2) (2005) 679–715.
[5] R.S. Mishima, M. Hohl, B. Linz, P. Sanders, D. Linz, Too fatty, too salty, too
western, Hypertension 72 (5) (2018) 1078–1080.
[6] H.J. Lambers Heerspink, F.A. Holtkamp, H.H. Parving, G.J. Navis, J.B. Lewis, E.
Ritz, P.A. de Graeff, D. de Zeeuw, Moderation of dietary sodium potentiates the
renal and cardiovascular protective effects of angiotensin receptor blockers,
Kidney Int. 82 (3) (2012) 330–337.
[7] B. Williams, G. Mancia, W. Spiering, E. Agabiti-Rosei, M. Azizi, M. Burnier, D.L.
Clement, A. Coca, G. de Simone, A. Dominiczak, T. Kahan, F. Mahfoud, J. Redon,
L. Ruilope, A. Zanchetti, M. Kerins, S.E. Kjeldsen, R. Kreutz, S. Laurent, G.Y.H. Lip,
R. McManus, K. Narkiewicz, F. Ruschitzka, R.E. Schmieder, E. Shlyakhto, C.
Tsioufis, V. Aboyans, I. Desormais, E.S.D. Group, 2018 ESC/ESH Guidelines for
the management of arterial hypertension: The Task Force for the management
of arterial hypertension of the European Society of Cardiology (ESC) and the
European Society of Hypertension (ESH), Eur. Heart J. 39 (33) (2018) 3021–
3104.
[8] H.O. Dickinson, J.M. Mason, D.J. Nicolson, F. Campbell, F.R. Beyer, J.V. Cook, B.
Williams, G.A. Ford, Lifestyle interventions to reduce raised blood pressure: a
systematic review of randomized controlled trials, J. Hypertens. 24 (2) (2006)
215–233.
[9] M. Herrera, T.M. Coffman, The kidney and hypertension: novel insights from
transgenic models, Curr. Opin. Nephrol. Hypertens. 21 (2) (2012) 171–178.
[10] K. Smiljanec, S.L. Lennon, Sodium, hypertension, and the gut: does the gut
microbiota go salty?, Am. J. Physiol. Heart Circ. Physiol. 317 (6) (2019) H1173–
H1182.
[11] J. Titze, Sodium balance is not just a renal affair, Curr. Opin. Nephrol.
Hypertens. 23 (2) (2014) 101–105.
[12] H.M. Wadei, S.C. Textor, The role of the kidney in regulating arterial blood
pressure, Nat. Rev. Nephrol. 8 (10) (2012) 602–609.
[13] S. Horita, G. Seki, H. Yamada, M. Suzuki, K. Koike, T. Fujita, Roles of renal
proximal tubule transport in the pathogenesis of hypertension, Curr.
Hypertens. Rev. 9 (2) (2013) 148–155.
[14] N.C. Zachos, M. Tse, M. Donowitz, Molecular physiology of intestinal Na+/H+
exchange, Annu. Rev. Physiol. 67 (2005) 411–443.
[15] J. Pacha, Sodium balance and jejunal ion and water absorption in Dahl salt-
sensitive and salt-resistant rats, Clin. Exp. Pharmacol. Physiol. 25 (3–4) (1998)
220–224.
[16] Y. Jia, G. Jia, Role of intestinal Na(+)/H(+) exchanger inhibition in the
prevention of cardiovascular and kidney disease, Ann. Transl. Med. 3 (7)
(2015) 91.
[17] N. Broere, M. Chen, A. Cinar, A.K. Singh, J. Hillesheim, B. Riederer, M.
Lunnemann, I. Rottinghaus, A. Krabbenhoft, R. Engelhardt, B. Rausch, E.J.
Weinman, M. Donowitz, A. Hubbard, O. Kocher, H.R. de Jonge, B.M. Hogema, U.
Seidler, Defective jejunal and colonic salt absorption and alteredNa(+)/H (+)
exchanger 3 (NHE3) activity in NHE regulatory factor 1 (NHERF1) adaptor
protein-deficient mice, Pflugers Arch. 457 (5) (2009) 1079–1091.
[18] D. Linz, K. Wirth, W. Linz, H.O. Heuer, W. Frick, A. Hofmeister, U. Heinelt, P.
Arndt, U. Schwahn, M. Bohm, H. Ruetten, Antihypertensive and laxative effects
by pharmacological inhibition of sodium-proton-exchanger subtype 3-
mediated sodium absorption in the gut, Hypertension 60 (6) (2012) 1560–
1567.
[19] P.J. Schultheis, L.L. Clarke, P. Meneton, M.L. Miller, M. Soleimani, L.R. Gawenis,
T.M. Riddle, J.J. Duffy, T. Doetschman, T. Wang, G. Giebisch, P.S. Aronson, J.N.
Lorenz, G.E. Shull, Renal and intestinal absorptive defects in mice lacking the
NHE3 Na+/H+ exchanger, Nat. Genet. 19 (3) (1998) 282–285.
[20] M.A. Gurney, D. Laubitz, F.K. Ghishan, P.R. Kiela, Pathophysiology of intestinal
Na(+)/H(+) exchange, Cell Mol. Gastroenterol. Hepatol. 3 (1) (2017) 27–40.
[21] J. Yang, P.A. Jose, C. Zeng, Gastrointestinal-renal axis: role in the regulation of
blood pressure, J. Am. Heart Assoc. 6 (3) (2017).hagen from ClinicalKey.com by Elsevier on September 10, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
B. Linz et al. / IJC Heart & Vasculature 29 (2020) 100591 7[22] J.B. Furness, L.R. Rivera, H.J. Cho, D.M. Bravo, B. Callaghan, The gut as a sensory
organ, Nat. Rev. Gastroenterol. Hepatol. 10 (12) (2013) 729–740.
[23] Y. Chen, L.D. Asico, S. Zheng, V.A. Villar, D. He, L. Zhou, C. Zeng, P.A. Jose,
Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis,
Hypertension 62 (5) (2013) 927–933.
[24] P.J. Turnbaugh, R.E. Ley, M. Hamady, C.M. Fraser-Liggett, R. Knight, J.I. Gordon,
The human microbiome project, Nature 449 (7164) (2007) 804–810.
[25] I. Cho, M.J. Blaser, The human microbiome: at the interface of health and
disease, Nat. Rev. Genet. 13 (4) (2012) 260–270.
[26] N. Wilck, M.G. Matus, S.M. Kearney, S.W. Olesen, K. Forslund, H. Bartolomaeus,
S. Haase, A. Mahler, A. Balogh, L. Marko, O. Vvedenskaya, F.H. Kleiner, D.
Tsvetkov, L. Klug, P.I. Costea, S. Sunagawa, L. Maier, N. Rakova, V. Schatz, P.
Neubert, C. Fratzer, A. Krannich, M. Gollasch, D.A. Grohme, B.F. Corte-Real, R.G.
Gerlach, M. Basic, A. Typas, C. Wu, J.M. Titze, J. Jantsch, M. Boschmann, R.
Dechend, M. Kleinewietfeld, S. Kempa, P. Bork, R.A. Linker, E.J. Alm, D.N.
Muller, Salt-responsive gut commensal modulates TH17 axis and disease,
Nature 551 (7682) (2017) 585–589.
[27] C.A. Harrison, D. Laubitz, C.L. Ohland, M.T. Midura-Kiela, K. Patil, D.G.
Besselsen, D.R. Jamwal, C. Jobin, F.K. Ghishan, P.R. Kiela, Microbial dysbiosis
associated with impaired intestinal Na(+)/H(+) exchange accelerates and
exacerbates colitis in ex-germ free mice, Mucosal Immunol. 11 (5) (2018)
1329–1341.
[28] G.M. Felker, C.M. O’Connor, E. Braunwald, I. Heart, Failure Clinical Research
Network, Loop diuretics in acute decompensated heart failure: necessary?
Evil? A necessary evil?, Circ. Heart Fail 2 (1) (2009) 56–62.
[29] D. Charmot, Non-systemic drugs: a critical review, Curr. Pharm. Des. 18 (10)
(2012) 1434–1445.
[30] A.G. Spencer, E.D. Labonte, D.P. Rosenbaum, C.F. Plato, C.W. Carreras, M.R.
Leadbetter, K. Kozuka, J. Kohler, S. Koo-McCoy, L. He, N. Bell, J. Tabora, K.M.
Joly, M. Navre, J.W. Jacobs, D. Charmot, Intestinal inhibition of the Na+/H+
exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in
humans, Sci. Transl. Med. 6 (227) (2014) 227–236.
[31] M. Zielinska, A. Wasilewski, J. Fichna, Tenapanor hydrochloride for the
treatment of constipation-predominant irritable bowel syndrome, Expert
Opin. Invest. Drugs 24 (8) (2015) 1093–1099.
[32] D.P. Rosenbaum, A. Yan, J.W. Jacobs, Pharmacodynamics, safety, and
tolerability of the NHE3 inhibitor tenapanor: two trials in healthy
volunteers, Clin. Drug Invest. 38 (4) (2018) 341–351.
[33] S. Johansson, D.P. Rosenbaum, M. Knutsson, M. Leonsson-Zachrisson, A phase 1
study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of
tenapanor in healthy Japanese volunteers, Clin. Exp. Nephrol. 21 (3) (2017)
407–416.
[34] G.A. Block, D.P. Rosenbaum, M. Leonsson-Zachrisson, M. Astrand, S. Johansson,
M. Knutsson, A.M. Langkilde, G.M. Chertow, Effect of tenapanor on serum
phosphate in patients receiving hemodialysis, J. Am. Soc. Nephrol.: JASN 28 (6)
(2017) 1933–1942.
[35] E.D. Labonte, C.W. Carreras, M.R. Leadbetter, K. Kozuka, J. Kohler, S. Koo-
McCoy, L. He, E. Dy, D. Black, Z. Zhong, I. Langsetmo, A.G. Spencer, N. Bell, D.
Deshpande, M. Navre, J.G. Lewis, J.W. Jacobs, D. Charmot, Gastrointestinal
inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption
and protects against vascular calcification in CKD, J. Am. Soc. Nephrol.: JASN 26
(5) (2015) 1138–1149.
[36] G.A. Block, D.P. Rosenbaum, A. Yan, G.M. Chertow, Efficacy and safety of
tenapanor in patients with hyperphosphatemia receiving maintenance
hemodialysis: a randomized phase 3 trial, J. Am. Soc. Nephrol.: JASN 30 (4)
(2019) 641–652.
[37] G.A. Block, D.P. Rosenbaum, M. Leonsson-Zachrisson, B.V. Stefansson, T.
Ryden-Bergsten, P.J. Greasley, S.A. Johansson, M. Knutsson, B.C. Carlsson,
Effect of tenapanor on interdialytic weight gain in patients on hemodialysis,
Clin. J. Am. Soc. Nephrol.: CJASN 11 (9) (2016) 1597–1605.
[38] S. Johansson, D.P. Rosenbaum, M. Ahlqvist, H. Rollison, M. Knutsson, B.
Stefansson, M. Elebring, Effects of tenapanor on cytochrome P450-
mediated drug-drug interactions, Clin. Pharmacol. Drug Dev. 6 (5) (2017)
466–475.
[39] N.A. Graudal, A.M. Galloe, P. Garred, Effects of sodium restriction on blood
pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a
meta-analysis, JAMA 279 (17) (1998) 1383–1391.
[40] M.W. Musch, Y.C. Li, E.B. Chang, Angiotensin II directly regulates intestinal
epithelial NHE3 in Caco2BBE cells, BMC Physiol. 9 (2009) 5.
[41] W.D. Chey, A.J. Lembo, D.P. Rosenbaum, Efficacy of tenapanor in treating
patients with irritable bowel syndrome with constipation: a 12-week,
placebo-controlled phase 3 trial (T3MPO-1), Am. J. Gastroenterol. 115 (2)
(2020) 281–293.
[42] W.D. Chey, A.J. Lembo, D.P. Rosenbaum, Tenapanor treatment of patients with
constipation-predominant irritable bowel syndrome: a phase 2, randomized,
placebo-controlled efficacy and safety trial, Am. J. Gastroenterol. 112 (5)
(2017) 763–774.
[43] B. Linz, M. Hohl, J.C. Reil, M. Bohm, D. Linz, Inhibition of NHE3-mediated
sodium absorption in the gut reduced cardiac end-organ damage without
deteriorating renal function in obese spontaneously hypertensive rats, J.
Cardiovasc. Pharmacol. 67 (3) (2016) 225–231.
[44] M. Hohl, D.H. Lau, A. Muller, A.D. Elliott, B. Linz, R. Mahajan, J.M.L. Hendriks, M.
Bohm, U. Schotten, P. Sanders, D. Linz, Concomitant obesity and metabolicDownloaded for Anonymous User (n/a) at BS - University of Copenhag
For personal use only. No other uses without permission. Csyndrome add to the atrial arrhythmogenic phenotype in male hypertensive
rats, J. Am. Heart Assoc. 6 (9) (2017).
[45] B. Linz, M. Hohl, R. Mishima, A. Saljic, D.H. Lau, T. Jespersen, U. Schotten, P.
Sanders, D. Linz, Pharmacological inhibition of sodium-proton-exchanger
subtype 3-mediated sodium absorption in the gut reduces atrial fibrillation
susceptibility in obese spontaneously hypertensive rats, Int. J. Cardiol. Heart
Vasculat. 28 (2020) 100534.
[46] N.S. Sankar, D. Donaldson, Lessons to be learned: a case study approach
diuretic therapy and a laxative causing electrolyte and water imbalance, loss
of attention, a fall and subsequent fractures of the tibia and fibula in an elderly
lady, J. R. Soc. Promot. Health 118 (4) (1998) 237–240.
[47] J.H. Cho, M.W. Musch, C.M. Bookstein, R.L. McSwine, K. Rabenau, E.B. Chang,
Aldosterone stimulates intestinal Na+ absorption in rats by increasing NHE3
expression of the proximal colon, Am. J. Physiol. 274 (3) (1998) C586–C594.
[48] J.A. Dominguez Rieg, S. de la Mora Chavez, T. Rieg, Novel developments in
differentiating the role of renal and intestinal sodium hydrogen exchanger 3,
Am. J. Physiol. Regul. Integr. Comp. Physiol. 311 (6) (2016) R1186–R1191.
[49] F. Alexander, The effect of diuretics on the faecal excretion of water and
electrolytes in horses, Br. J. Pharmacol. 60 (4) (1977) 589–593.
[50] R.S. Mishima, A.D. Elliott, P. Sanders, D. Linz, Microbiome and atrial fibrillation,
Int. J. Cardiol. 255 (2018) 103–104.
[51] R.S. Mishima, A.D. Elliott, P. Sanders, D. Linz, Gastrointestinal sodium
absorption, microbiome, and hypertension, Nat. Rev. Cardiol. 14 (11) (2017)
693.
[52] M. Tanaka, H. Itoh, Hypertension as a metabolic disorder and the novel role of
the gut, Curr. Hypertens. Rep. 21 (8) (2019) 63.
[53] J.L. Pluznick, Microbial short-chain fatty acids and blood pressure regulation,
Curr. Hypertens. Rep. 19 (4) (2017) 25.
[54] J.L. Pluznick, R.J. Protzko, H. Gevorgyan, Z. Peterlin, A. Sipos, J. Han, I. Brunet, L.
X. Wan, F. Rey, T. Wang, S.J. Firestein, M. Yanagisawa, J.I. Gordon, A. Eichmann,
J. Peti-Peterdi, M.J. Caplan, Olfactory receptor responding to gut microbiota-
derived signals plays a role in renin secretion and blood pressure regulation,
Proc. Natl. Acad. Sci. U S A 110 (11) (2013) 4410–4415.
[55] B. Afsar, N.D. Vaziri, G. Aslan, K. Tarim, M. Kanbay, Gut hormones and gut
microbiota: implications for kidney function and hypertension, J. Am. Soc.
Hypertens. 10 (12) (2016) 954–961.
[56] A. Psichas, M.L. Sleeth, K.G. Murphy, L. Brooks, G.A. Bewick, A.C. Hanyaloglu, M.
A. Ghatei, S.R. Bloom, G. Frost, The short chain fatty acid propionate stimulates
GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents, Int. J. Obes.
(Lond) 39 (3) (2015) 424–429.
[57] J. Shimizu, T. Kubota, E. Takada, K. Takai, N. Fujiwara, N. Arimitsu, M.A.
Murayama, Y. Ueda, S. Wakisaka, T. Suzuki, N. Suzuki, Propionate-producing
bacteria in the intestine may associate with skewed responses of IL10-
producing regulatory T cells in patients with relapsing polychondritis, PLoS
ONE 13 (9) (2018) e0203657.
[58] V.V. Lima, S.M. Zemse, C.W. Chiao, G.F. Bomfim, R.C. Tostes, R. Clinton Webb, F.
R. Giachini, Interleukin-10 limits increased blood pressure and vascular RhoA/
Rho-kinase signaling in angiotensin II-infused mice, Life Sci. 145 (2016) 137–
143.
[59] H. Bartolomaeus, A. Balogh, M. Yakoub, S. Homann, L. Marko, S. Hoges, D.
Tsvetkov, A. Krannich, S. Wundersitz, E.G. Avery, N. Haase, K. Kraker, L. Hering,
M. Maase, K. Kusche-Vihrog, M. Grandoch, J. Fielitz, S. Kempa, M. Gollasch, Z.
Zhumadilov, S. Kozhakhmetov, A. Kushugulova, K.U. Eckardt, R. Dechend, L.C.
Rump, S.K. Forslund, D.N. Muller, J. Stegbauer, N. Wilck, Short-chain fatty acid
propionate protects from hypertensive cardiovascular damage, Circulation 139
(11) (2019) 1407–1421.
[60] A. Dalla Via, G. Gargari, V. Taverniti, G. Rondini, I. Velardi, V. Gambaro, G.L.
Visconti, V. De Vitis, C. Gardana, E. Ragg, A. Pinto, P. Riso, S. Guglielmetti,
Urinary TMAO levels are associated with the taxonomic composition of the gut
microbiota and with the choline TMA-Lyase Gene (cutC) harbored by
enterobacteriaceae, Nutrients 12 (1) (2019).
[61] V.B. Polsinelli, L. Marteau, S.J. Shah, The role of splanchnic congestion and the
intestinal microenvironment in the pathogenesis of advanced heart failure,
Curr. Opin. Support Palliat. Care 13 (1) (2019) 24–30.
[62] C. Antza, S. Stabouli, V. Kotsis, Gut microbiota in kidney disease and
hypertension, Pharmacol. Res. 130 (2018) 198–203.
[63] G. Hecht, K. Hodges, R.K. Gill, F. Kear, S. Tyagi, J. Malakooti, K. Ramaswamy, P.K.
Dudeja, Differential regulation of Na+/H+ exchange isoform activities by
enteropathogenic E. coli in human intestinal epithelial cells, Am. J. Physiol.
Gastrointest. Liver Physiol. 287 (2) (2004) G370–G378.
[64] M.A. Engevik, K.A. Engevik, M.B. Yacyshyn, J. Wang, D.J. Hassett, B. Darien, B.R.
Yacyshyn, R.T. Worrell, Human Clostridium difficile infection: inhibition of
NHE3 and microbiota profile, Am. J. Physiol. Gastrointest. Liver Physiol. 308 (6)
(2015) G497–G509.
[65] V. Singh, G. Raheja, A. Borthakur, A. Kumar, R.K. Gill, A. Alakkam, J. Malakooti,
P.K. Dudeja, Lactobacillus acidophilus upregulates intestinal NHE3 expression
and function, Am. J. Physiol. Gastrointest. Liver Physiol. 303 (12) (2012)
G1393–G1401.
[66] D. Laubitz, C.A. Harrison, M.T. Midura-Kiela, R. Ramalingam, C.B. Larmonier, J.
H. Chase, J.G. Caporaso, D.G. Besselsen, F.K. Ghishan, P.R. Kiela, Reduced
epithelial Na+/H+ exchange drives gut microbial dysbiosis and promotes
inflammatory response in T cell-mediated murine colitis, PLoS ONE 11 (4)
(2016) e0152044.en from ClinicalKey.com by Elsevier on September 10, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
